Title Page, Copyright, Dedication

pdf iconDownload PDF

pp. 1-6

Contents

pdf iconDownload PDF

pp. vii-viii

read more

Preface

pdf iconDownload PDF

pp. ix-xiv

This book is about betting on commercial biotech development in three key Asian economies: South Korea, Taiwan, and Singapore. After more than two hundred interviews with informants in the field, over twenty research trips to the region, and countless hours in the library and in front of my computer, ...

read more

Introduction: Betting on Biotech

pdf iconDownload PDF

pp. 1-15

Since the 1990s, Korea, Taiwan, and Singapore have poured billions of dollars into the commercial development of biotech. Biotech and life sciences industries more generally have been hailed as the next “star” and “pillar” industries in what are already very advanced economies, and the aspirations of those economies are not modest. ...

read more

1. From Mitigating Risk to Managing Uncertainty

pdf iconDownload PDF

pp. 16-42

Industrial development and diversification are about taking risk. Encouraging the growth of industry in new and unfamiliar sectors is always risky. It invariably involves costs, and the rewards are uncertain. Yet it is important to consider different kinds and levels of risk in industrial upgrading. ...

read more

2. Reorganizing the State

pdf iconDownload PDF

pp. 43-80

The postwar economic miracles in Korea, Taiwan, and Singapore were facilitated by the developmental state’s strategic capacity and willingness to coordinate the allocation of resources in order to mitigate risk. By mitigating the risks of industrial upgrading, the state encouraged otherwise risk-averse entrepreneurs ...

read more

3. Organizing Bio-industry

pdf iconDownload PDF

pp. 81-112

81 Chapter 3 Organizing Bio-industry Commercializing biotech is an extraordinarily complex process. It involves the generation of new knowledge in the upstream and the translation of knowledge into usable technological applications that bear market value. Marketable novel technologies need not be just cutting-edge knowledge but also include innovative business models ...

read more

4. Manufacturing “Progress”

pdf iconDownload PDF

pp. 113-139

In late 2007, I gave a talk in Taiwan on the development of commercial biotech. By then, Taiwan’s drive to upgrade into biotech had been in full gear for nearly two decades, and Taiwan’s aspirations in the sector had become a central part of the discourse about the island’s economic future. ...

read more

5. Regulatory Uncertainty

pdf iconDownload PDF

pp. 140-164

This chapter focuses on a very specific dimension of commercial biotech development—regulation—and the ways in which the state in Korea, Taiwan, and Singapore has both contributed to and attempted to manage regulatory uncertainty. Regulatory considerations are an important aspect of the biotech innovation process, ...

read more

Conclusion: Beyond the Developmental State

pdf iconDownload PDF

pp. 165-190

The race is on. Ever since the rediscovery in the 1970s of the biological heuristic, which prompted the faint and distant hope for a new generation of cutting-edge health technologies, the world has focused tremendous attention on the promise of commercial biotech. ...

Index

pdf iconDownload PDF

pp. 191-200